CA2686517A1 - Azetidine derivatives and their use as prostaglandin e2 antagonists - Google Patents

Azetidine derivatives and their use as prostaglandin e2 antagonists Download PDF

Info

Publication number
CA2686517A1
CA2686517A1 CA002686517A CA2686517A CA2686517A1 CA 2686517 A1 CA2686517 A1 CA 2686517A1 CA 002686517 A CA002686517 A CA 002686517A CA 2686517 A CA2686517 A CA 2686517A CA 2686517 A1 CA2686517 A1 CA 2686517A1
Authority
CA
Canada
Prior art keywords
azetidine
compound
prodrug
solvate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002686517A
Other languages
English (en)
French (fr)
Inventor
Kevin Neil Dack
Siew Kuen Yeap
Sarah Elizabeth Skerratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2686517A1 publication Critical patent/CA2686517A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002686517A 2007-05-10 2008-04-28 Azetidine derivatives and their use as prostaglandin e2 antagonists Abandoned CA2686517A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US60/917,081 2007-05-10
US1303007P 2007-12-12 2007-12-12
US61/013,030 2007-12-12
PCT/IB2008/001070 WO2008139287A1 (en) 2007-05-10 2008-04-28 Azetidine derivatives and their use as prostaglandin e2 antagonists

Publications (1)

Publication Number Publication Date
CA2686517A1 true CA2686517A1 (en) 2008-11-20

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002686517A Abandoned CA2686517A1 (en) 2007-05-10 2008-04-28 Azetidine derivatives and their use as prostaglandin e2 antagonists

Country Status (27)

Country Link
US (1) US20080280877A1 (enExample)
EP (1) EP2155666A1 (enExample)
JP (1) JP2010526801A (enExample)
KR (1) KR20100009582A (enExample)
CN (1) CN101679235A (enExample)
AP (1) AP2009005047A0 (enExample)
AR (1) AR066524A1 (enExample)
AU (1) AU2008249744A1 (enExample)
BR (1) BRPI0811444A2 (enExample)
CA (1) CA2686517A1 (enExample)
CL (1) CL2008001305A1 (enExample)
CO (1) CO6260066A2 (enExample)
CR (1) CR11101A (enExample)
DO (1) DOP2009000256A (enExample)
EA (1) EA200901381A1 (enExample)
EC (1) ECSP099727A (enExample)
GT (1) GT200900293A (enExample)
IL (1) IL201874A0 (enExample)
MA (1) MA31366B1 (enExample)
MX (1) MX2009011998A (enExample)
PA (1) PA8779601A1 (enExample)
PE (1) PE20090282A1 (enExample)
SV (1) SV2009003407A (enExample)
TN (1) TN2009000470A1 (enExample)
TW (1) TW200904409A (enExample)
UY (1) UY31070A1 (enExample)
WO (1) WO2008139287A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063365A1 (en) * 2007-11-15 2009-05-22 Pfizer Limited Azetidines as ep2 antagonists
JP2012508225A (ja) 2008-11-10 2012-04-05 ファイザー・リミテッド ピロリジン
CA2757480A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
CA3157279A1 (en) * 2019-11-21 2021-05-27 Paul Richard Sebahar Trpv4 receptor ligands
WO2022272062A1 (en) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
HRP20110498T1 (hr) * 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
UY31070A1 (es) 2009-01-05
CL2008001305A1 (es) 2008-07-18
CO6260066A2 (es) 2011-03-22
AP2009005047A0 (en) 2009-12-31
KR20100009582A (ko) 2010-01-27
US20080280877A1 (en) 2008-11-13
TW200904409A (en) 2009-02-01
AR066524A1 (es) 2009-08-26
EA200901381A1 (ru) 2010-06-30
GT200900293A (es) 2010-05-17
WO2008139287A1 (en) 2008-11-20
JP2010526801A (ja) 2010-08-05
CR11101A (es) 2009-12-04
IL201874A0 (en) 2010-06-16
TN2009000470A1 (fr) 2011-03-31
PA8779601A1 (es) 2009-01-23
MX2009011998A (es) 2009-11-19
MA31366B1 (fr) 2010-05-03
AU2008249744A1 (en) 2008-11-20
CN101679235A (zh) 2010-03-24
PE20090282A1 (es) 2009-03-27
EP2155666A1 (en) 2010-02-24
DOP2009000256A (es) 2009-11-30
ECSP099727A (es) 2009-12-28
BRPI0811444A2 (pt) 2014-10-29
SV2009003407A (es) 2010-01-12

Similar Documents

Publication Publication Date Title
US20080280877A1 (en) Azetidines
EP2593428B1 (en) N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2717750C (en) Azetidine derivatives
WO2012095781A1 (en) Indazole derivatives as sodium channel inhibitors
NO338420B1 (no) Substituerte triazolderivater som oksytocinantagonister
WO2006109846A1 (ja) トリアゾール誘導体およびその用途
US8278343B2 (en) Pyrrolidines
US20100256109A1 (en) Azetidines As EP2 Antagonists
US7449462B2 (en) Triazole derivatives which inhibit vasopressin antagonistic activity
WO2015181797A1 (en) Benzenesulfonamides useful as sodium channel inhibitors
HK1139661A (en) Azetidine derivatives and their use as prostaglandin e2 antagonists
HK1158197A (en) Pyrrolidines
HK1113927B (en) Substituted triazole derivatives as oxytocin antagonists
HK1127342A1 (en) Substituted imidazole derivatives and there use as ptpase inhibitors
HK1127342B (en) Substituted imidazole derivatives and there use as ptpase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130121